# Bernard Peissel

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 122 papers | 5,707 citations | 37 h-index | 73 g-index |
| 123 ext. papers | 6,707 ext. citations | 7.8 avg, IF | 3.72 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 122 | The Impact of Mediterranean Dietary Intervention on Metabolic and Hormonal Parameters According to Variant Type.. *Frontiers in Genetics*, **2022**, 13, 820878 | 4.5 | 0 |
| 121 | Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.. *Frontiers in Oncology*, **2022**, 12, 857515 | 5.3 | 0 |
| 120 | Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. *Clinical Breast Cancer*, **2021**, 21, e168-e176 | 3 | 9 |
| 119 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**, | 9.7 | 3 |
| 118 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86 | 8.3 | 1 |
| 117 | Analysis of Italian Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. *Cancers*, **2021**, 13, | 6.6 | 5 |
| 116 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581 | 36.3 | 76 |
| 115 | The Spectrum of Protein Truncating Variants in European Breast Cancer Cases. *Cancers*, **2020**, 12, | 6.6 | 7 |
| 114 | Analysis of and Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer. *Cancers*, **2020**, 12, | 6.6 | 5 |
| 113 | Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638 | 10.1 | 22 |
| 112 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73 | 36.3 | 56 |
| 111 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666 | 8.1 | 34 |
| 110 | BRCA1/2 Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers. *Cancers*, **2020**, 12, | 6.6 | 2 |
| 109 | Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?. *Psycho-Oncology*, **2019**, 28, 1871-1878 | 3.9 | 6 |
| 108 | The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38 | 7.8 | 12 |
| 107 | Constitutive Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. *Cancers*, **2019**, 11, | 6.6 | 10 |
| 106 | Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition. *Cancer Genetics*, **2018**, 221, 38-45 | 2.3 | 1 |

| | | | |
|---|---|---|---|
| 105 | Adherence to Mediterranean Diet and Metabolic Syndrome in BRCA Mutation Carriers. *Integrative Cancer Therapies*, **2018**, 17, 153-160 | 3 | 21 |
| 104 | Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. *Genetics in Medicine*, **2018**, 20, 452-457 | 8.1 | 44 |
| 103 | A Dietary Intervention to Lower Serum Levels of IGF-I in Mutation Carriers. *Cancers*, **2018**, 10, | 6.6 | 14 |
| 102 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691 | 36.3 | 190 |
| 101 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778 | 36.3 | 186 |
| 100 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250 | 2.2 | 101 |
| 99 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134 | 4.4 | 15 |
| 98 | Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. *Cancer*, **2017**, 123, 210-218 | 6.4 | 22 |
| 97 | Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. *PLoS ONE*, **2017**, 12, e0171663 | 3.7 | 6 |
| 96 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401 | 4.9 | 15 |
| 95 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375 | 17.4 | 64 |
| 94 | Cardio-Oncology: The Carney Complex Type I. *Journal of the American College of Cardiology*, **2016**, 68, 1921-1923 | 15.1 | 2 |
| 93 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86 | 36.3 | 93 |
| 92 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108, | 9.7 | 65 |
| 91 | A targeted approach to genetic counseling in breast cancer patients: the experience of an Italian local project. *Tumori*, **2016**, 102, 45-50 | 1.7 | 3 |
| 90 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801 | 3.7 | 7 |
| 89 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811 | 5.8 | 121 |
| 88 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64 | 8.3 | 25 |

| | | | |
|---|---|---|---|
| 87 | Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. *European Journal of Internal Medicine*, **2016**, 32, 65-71 | 3.9 | 18 |
| 86 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15 | 8.3 | 58 |
| 85 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71 | 36.3 | 177 |
| 84 | FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55 | 5.6 | 68 |
| 83 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61 | 27.4 | 286 |
| 82 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91 | 4 | 17 |
| 81 | Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. *Familial Cancer*, **2015**, 14, 117-28 | 3 | 12 |
| 80 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16 | 4 | 20 |
| 79 | Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors. *Scientific Reports*, **2015**, 5, 15454 | 4.9 | 10 |
| 78 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61 | 8.3 | 16 |
| 77 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020 | 3.7 | 26 |
| 76 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84 | 5.6 | 36 |
| 75 | PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. *Genetics in Medicine*, **2014**, 16, 688-94 | 8.1 | 21 |
| 74 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46 | 5.6 | 28 |
| 73 | The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. *Clinical Genetics*, **2014**, 85, 7-15 | 4 | 26 |
| 72 | A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. *BMC Medical Genetics*, **2014**, 15, 59 | 2.1 | 8 |
| 71 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46 | 5.6 | 11 |
| 70 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256 | 6 | 33 |

| | | | |
|---|---|---|---|
| 69 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416 | 8.3 | 46 |
| 68 | Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. *PLoS ONE*, **2014**, 9, e86924 | 3.7 | 18 |
| 67 | miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. *PLoS ONE*, **2014**, 9, e87039 | 3.7 | 54 |
| 66 | First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. *BMC Cancer*, **2013**, 13, 46 | 4.8 | 28 |
| 65 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2 | 36.3 | 422 |
| 64 | X chromosome inactivation pattern in BRCA gene mutation carriers. *European Journal of Cancer*, **2013**, 49, 1136-41 | 7.5 | 8 |
| 63 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2 | 36.3 | 327 |
| 62 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212 | 6 | 209 |
| 61 | Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. *PLoS ONE*, **2013**, 8, e57173 | 3.7 | 46 |
| 60 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33 | 8.3 | 70 |
| 59 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702 | 4.7 | 31 |
| 58 | Sequencing analysis of SLX4/FANCP gene in Italian familial breast cancer cases. *PLoS ONE*, **2012**, 7, e31038 | 3.7 | 9 |
| 57 | Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. *Human Mutation*, **2012**, 33, 1665-75 | 4.7 | 42 |
| 56 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. *British Journal of Cancer*, **2012**, 106, 2016-24 | 8.7 | 25 |
| 55 | The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. *Breast Cancer Research and Treatment*, **2012**, 133, 805-7 | 4.4 | 28 |
| 54 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57 | 4 | 44 |
| 53 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47 | 4 | 411 |
| 52 | The role of genetic breast cancer susceptibility variants as prognostic factors. *Human Molecular Genetics*, **2012**, 21, 3926-39 | 5.6 | 75 |

| | | | |
|---|---|---|---|
| 51 | Exploring the link between MORF4L1 and risk of breast cancer. *Breast Cancer Research*, **2011**, 13, R40 | 8.3 | 16 |
| 50 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110 | 8.3 | 62 |
| 49 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. *British Journal of Cancer*, **2011**, 104, 1356-61 | 8.7 | 6 |
| 48 | Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. *Familial Cancer*, **2011**, 10, 521-8 | 3 | 25 |
| 47 | The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 125, 855-60 | 4.4 | 10 |
| 46 | PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. *Breast Cancer Research and Treatment*, **2011**, 126, 825-8 | 4.4 | 32 |
| 45 | Evidence for a link between TNFRSF11A and risk of breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 947-54 | 4.4 | 11 |
| 44 | Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations. *Breast Cancer Research and Treatment*, **2011**, 130, 207-15 | 4.4 | 11 |
| 43 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99 | 6.3 | 15 |
| 42 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21 | 5.6 | 62 |
| 41 | Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. *Endocrine-Related Cancer*, **2011**, 18, 519-27 | 5.7 | 23 |
| 40 | The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. *Journal of Medical Genetics*, **2011**, 48, 703-4 | 5.8 | 13 |
| 39 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16 | 9.7 | 37 |
| 38 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199 | 9.7 | 73 |
| 37 | Is there a Specific Magnetic Resonance Phenotype Characteristic of Hereditary Breast Cancer?. *Tumori*, **2010**, 96, 363-384 | 1.7 | 2 |
| 36 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54 | 10.1 | 147 |
| 35 | Two novel mutations affecting splicing in the IRF6 gene associated with van der Woude syndrome. *Journal of Craniofacial Surgery*, **2010**, 21, 1654-6 | 1.2 | 8 |
| 34 | Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. *Breast Cancer Research and Treatment*, **2010**, 124, 251-8 | 4.4 | 19 |

| | | | |
|---|---|---|---|
| 33 | An unusual BRCA2 allele carrying two splice site mutations. *Annals of Oncology*, **2009**, 20, 1143-4 | 10.3 | 7 |
| 32 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56 | 5.6 | 91 |
| 31 | SNPs in ultraconserved elements and familial breast cancer risk. *Carcinogenesis*, **2009**, 30, 544-5; author reply 546 | 4.6 | 22 |
| 30 | Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. *Journal of Investigative Dermatology*, **2009**, 129, 1759-68 | 4.3 | 46 |
| 29 | Clinical genetic testing for familial melanoma in Italy: a cooperative study. *Journal of the American Academy of Dermatology*, **2009**, 61, 775-82 | 4.5 | 39 |
| 28 | Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. *Modern Pathology*, **2008**, 21, 1262-70 | 9.8 | 15 |
| 27 | An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2008**, 99, 974-7 | 8.7 | 12 |
| 26 | Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis. *Annals of Human Genetics*, **2008**, 72, 310-8 | 2.2 | 17 |
| 25 | Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. *Journal of the National Cancer Institute*, **2008**, 100, 752-3; author reply 753-4 | 9.7 | 2 |
| 24 | Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. *European Journal of Cancer*, **2007**, 43, 601-6 | 7.5 | 38 |
| 23 | MRI in the Early Detection of Breast Cancer in Women with High Genetic Risk. *Tumori*, **2006**, 92, 517-523 | 1.7 | 35 |
| 22 | Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. *American Journal of Surgical Pathology*, **2006**, 30, 1222-30 | 6.7 | 112 |
| 21 | Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. *Journal of Human Genetics*, **2006**, 51, 209-216 | 4.3 | 23 |
| 20 | Loss of tyrosinase activity confers increased skin tumor susceptibility in mice. *Oncogene*, **2004**, 23, 4130-5 | 5.2 | 18 |
| 19 | The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. *Human Mutation*, **2004**, 24, 100-1 | 4.7 | 36 |
| 18 | Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. *Oncogene*, **2003**, 22, 7711-5 | 9.2 | 7 |
| 17 | Inhibition of both skin and lung tumorigenesis by Car-R mouse-derived cancer modifier loci. *International Journal of Cancer*, **2002**, 97, 580-3 | 7.5 | 4 |
| 16 | Use of intercross outbred mice and single nucleotide polymorphisms to map skin cancer modifier loci. *Mammalian Genome*, **2001**, 12, 291-4 | 3.2 | 8 |

| | | | |
|---|---|---|---|
| 15 | A cancer modifier role for parathyroid hormone-related protein. *Oncogene*, **2000**, 19, 5324-8 | 9.2 | 27 |
| 14 | Mapping of melanoma modifier loci in RET transgenic mice. *Japanese Journal of Cancer Research*, **2000**, 91, 1142-7 | | 12 |
| 13 | Linkage disequilibrium and haplotype mapping of a skin cancer susceptibility locus in outbred mice. *Mammalian Genome*, **2000**, 11, 979-81 | 3.2 | 13 |
| 12 | LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis. *American Journal of Human Genetics*, **1999**, 64, 62-9 | 11 | 95 |
| 11 | Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. *Nature Genetics*, **1997**, 17, 179-81 | 36.3 | 381 |
| 10 | Gene linkage analysis and DNA based detection of autosomal dominant polycystic kidney disease (ADPKD) in a newborn infant. Case report. *Journal of Perinatal Medicine*, **1995**, 23, 205-12 | 2.7 | 4 |
| 9 | Clinical applications of genetic linkage analysis for the molecular diagnostics of ADPKD, using DNA markers linked to the PKD1 and PKD2 genes. *Contributions To Nephrology*, **1995**, 115, 88-92 | 1.6 | 1 |
| 8 | Rapid DNA-based prenatal diagnosis of autosomal dominant polycystic kidney disease. *JAMA Pediatrics*, **1994**, 148, 1101-2 | | 2 |
| 7 | Single base pair deletions in exons 39 and 42 of the COL4A5 gene in Alport syndrome. *Human Molecular Genetics*, **1994**, 3, 201-2 | 5.6 | 16 |
| 6 | A novel frameshift deletion in type IV collagen alpha 5 gene in a juvenile-type Alport syndrome patient: an adenine deletion (2940/2943 del A) in exon 34 of COL4A5. *Human Mutation*, **1994**, 3, 386-90 | 4.7 | 16 |
| 5 | Prenatal testing in a fetus at risk for autosomal dominant polycystic kidney disease and autosomal recessive junctional epidermolysis bullosa with pyloric atresia. *American Journal of Medical Genetics Part A*, **1993**, 47, 1225-30 | | 5 |
| 4 | Prenatal diagnosis of autosomal dominant polycystic kidney disease using flanking DNA markers and the polymerase chain reaction. *Prenatal Diagnosis*, **1992**, 12, 513-24 | 3.2 | 9 |
| 3 | Linkage analysis for the diagnosis of autosomal dominant polycystic kidney disease, and for the determination of genetic heterogeneity in Italian families. *Clinical Genetics*, **1991**, 40, 287-97 | 4 | 11 |
| 2 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes | | 2 |
| 1 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | | 2 |